ArticleFrontiers in medicine2026
A trial of exosome rich stem cell secretome as a potential treatment for Hypermobile Ehlers-Danlos Syndrome.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hypermobile Type Ehlers-Danlos Syndrome (hEDS) accounts for 80%-90% of all Ehlers-Danlos cases. hEDS pathophysiology is uncertain. There is no diagnostic test. Symptoms include joint hypermobility, intractable and debilitating joint pain, chronic fatigue, brain fog, irritable bowel symptoms and mast cell activation syndrome. Treatment options are limited and ineffective. None are disease-modifying. This pilot study evaluated the safety and potential for efficacy of a novel biologic investigational product (IP) comprising an extracellular vesicle enriched secretome from human bone marrow-derived mesenchymal stem cells (hbm-MSC EVs). Method: Ten (10) hEDS patients were recruited and treated with up to four doses of IP by intravenous infusion for up to five months. Symptoms were assessed using a custom 9-criteria questionnaire addressing common symptoms and by observation at each infusion. Results: No treatment related adverse events were reported or noted. Statistically significant response was found before treatment and after treatment for the ten patients as a group. However, six (6) out of the ten (10) patient exhibited distinct, substantial, rapid, and sustained overall improvement of their symptoms within the study time frame. Due to time limitations of the study, a single distinct responder (one of six responders), with IND approval for continued treatment, was further treated and observed for an additional twelve (12) months. Treatment was ultimately stopped at the patient's request and for 32 months thereafter has lived in apparent remission without pain or any previous symptoms or signs of Hypermobile Ehlers-Danlos Syndrome. All five (5) prior distinct responders with discontinued treatment reverted to their pre-treatment condition. Conclusion: Results of this pilot study suggest that a randomized, controlled trial is warranted to evaluate the potential of the IP for treatment of hEDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.